Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Fri, 13.08.2021
Aspermont Limited
- A rising star in the digital media service industry
- Profitable & scalable XaaS model
- Uninterrupted growth for the past 5 years
Aspermont Limited is the global leader in business-to-business (B2B) media
for the resources sector. The company publishes subscription-based content
services for the mining, energy, agriculture, and technology [ … ]
Thu, 12.08.2021
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt
seine ADD-Empfehlung und erhöht das Kursziel von EUR 7,70 auf EUR 7,90.
Zusammenfassung:
PNE hat Zahlen für das 2. Quartal veröffentlicht, die leicht über unseren
Prognosen [ … ]
Wed, 11.08.2021
Aves One AG
Takeover offer for Aves One AG by consortium, takeover price at EUR 12.80
and thus close to the GBC price target, revaluation as soon as offer
available
A consortium consisting of Swiss Life Asset Managers (Switzerland) and
Vauban Infrastructure Partners (France) has made a voluntary public
takeover offer to the share-holders of Aves One AG on 6 [ … ]
Mon, 09.08.2021
The NAGA Group AG
Strong revenue growth and operating break-even achieved,
internationalisation and new products ensure further growth, price target
raised to EUR 9.10, Rating: BUY
Already in January 2021, The NAGA Group AG (short: NAGA) had published
preliminary figures for the past financial year 2020. On 26 July 2021, the
publication of the annual report confi [ … ]
Fri, 30.07.2021
Vectron Systems AG
1H 2021: New record figures for sales and earnings achieved, 2021 forecasts
slightly increased, target price: EUR21.55; rating: BUY
On 20 July 2021 Vectron Systems AG (short: Vectron) published
extraordinarily good preliminary figures for the second quarter 2021 and
thus for the first half-year 2021. After an increase in sales of +14.7% to
EUR 8 [ … ]
Thu, 29.07.2021
Deutsche Rohstoff AG
First Berlin Equity Research hat ein Research Update zu Deutsche Rohstoff
AG (ISIN: DE000A0XYG76) veröffentlicht. Analyst Simon Scholes bestätigt
seine BUY-Empfehlung und erhöht das Kursziel von EUR 17,00 auf EUR 24,00.
Zusammenfassung:
Die Öl- und Gaspreise sind seit unserem letzten Update vom 20. April weiter
gestiegen. Die [ … ]
Wed, 28.07.2021
Cryptology Asset Group PLC
Cryptology share split in a ratio of 1:20 executed; price target increased
to (after split) EUR18.35; Rating: Buy
Cryptology Asset Group plc (Cryptology for short) has completed the
previously announced 1:20 share split as of July 27, 2021. The resolution
for the share split was approved by shareholders at an extraordinary
general meeting on Jul [ … ]
Tue, 27.07.2021
ADVA Optical Networking SE
First Berlin Equity Research hat ein Research Update zu ADVA Optical
Networking SE (ISIN: DE0005103006) veröffentlicht. Analyst Simon Scholes
stuft die Aktie auf ADD herab aber erhöht das Kursziel von EUR 13,00 auf
EUR 14,40.
Zusammenfassung:
Der Umsatz von ADVA kletterte in Q2/21 um 3,0 % auf €149,4 Mio. (FBe:
€150,1 Mio.; Q [ … ]
Fri, 23.07.2021
Diversified Energy PLC
First Berlin Equity Research hat ein Research Update zu Diversified Energy
PLC (ISIN: GB00BYX7JT74) veröffentlicht. Analyst Simon Scholes bestätigt
seine BUY-Empfehlung und bestätigt sein Kursziel von GBp 140,00.
Zusammenfassung:
Der jüngste Kauf von Assets von Tanos Energy Holdings ist der dritte in
einer Reihe von Deals, di [ … ]
Tue, 20.07.2021
MagForce AG
- Approval for prostate treatment imminent,
- New treatment devices to be installed in Europe,
- Strong growth and break-even expected from 2022 onwards
Despite pandemic-related restrictions, MagForce AG made further progress in
2020 in the commercialisation of its own technology. For the alreadyapproved
treatment of malignant brain tumours in [ … ]